Methods of treating developmental disorders using pipradrol

Abstract

Methods of treating developmental disorders by administering a pharmaceutical composition of pipradrol or a pharmaceutically acceptable salt thereof are provided. The methods may be used to treat conditions such as epilepsy, Landau-Kleffner Syndrome, Lennox-Gastaut syndrome (LGS) and Dravet syndrome.

1 - 7 . (canceled) 
     
     
         8 . A method of treating a seizure disorder comprising administering to a patient in need thereof pipradrol or a pharmaceutically acceptable salt thereof. 
     
     
         9 . The method of  claim 8  wherein the seizure disorder is selected from the group consisting of epilepsy, Landau-Kleffner syndrome, benign rolandic epilepsy (BRE), intractable childhoof epilepsy (ICE), childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), infantile spasms (or West syndrome), a sodium channel protein type 1 subunit alpha (Scn1A)-related disorder, and Lennox-Gastaut syndrome (LGS). 
     
     
         10 . The method of  claim 8  wherein the seizure disorder is a childhood epilepsy syndrome selected from the group consisting of benign rolandic epilepsy (BRE), childhood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME), infantile spasms (or West syndrome), and Lennox-Gastaut syndrome (LGS). 
     
     
         11 . The method of  claim 8  wherein the seizure disorder is epilepsy. 
     
     
         12 . The method of  claim 8  wherein the seizure disorder is Lennox-Gastaut syndrome (LGS). 
     
     
         13 . The method of  claim 8  wherein the seizure disorder is Landau-Kleffner syndrome. 
     
     
         14 . The method of  claim 8  wherein the patient is administered a daily dosage in the range of about 0.1 mg to about 50 mg pipradrol or a pharmaceutically acceptable salt thereof 
     
     
         15 . The method of  claim 8  wherein the patient is administered pharmaceutical composition comprising about 0.1 mg to about 50 mg pipradrol or a pharmaceutically acceptable salt thereof. 
     
     
         16 . The method of  claim 8  wherein the composition provides reduction in the frequency of seizures, the severity of seizures, or a combination thereof in a patient diagnosed with the childhood epilepsy syndrome. 
     
     
         17 . The method of  claim 8  further comprising administering a second compound selected from the group consisting of gaboxadol, acetazolamide, carbamazepine, clobazam, clonazepam, eslicarbazepine acetate, ethosuximide, gabapentin, lacosamide, lamotrigine, leviteracetam, nitrazepam, oxcarbazepine, perampanel, piracetam, phenobarbital, phenytoin, pregabalin, primidone, retigabine, rufinamide, sodium valproate, stiripentol, tiagabine, topiramate, vigabatrin, and zonisamide.